Mesoblast’s allogeneic or ‘off-the-shelf’ regenerative medicine products focus on repair of damaged tissues and modulation of inflammatory responses in conditions with significant unmet medical needs.
Mesoblast Limited has leveraged its proprietary technology platform, which is based on specialized cells known as mesenchymal lineage adult stem cells, to establish a broad portfolio of late-stage regenerative medicine product candidates.
The lead therapeutic product candidates under investigation include:
- MPC-150-IM for chronic congestive heart failure
- MPC-06-ID for chronic discogenic low back pain
- MSC-100-IV for acute graft versus host disease, and
- MPC-300-IV for biologic refractory rheumatoid arthritis, and diabetic nephropathy.
Additionally, Mesoblast has a significant pipeline of earlier-stage programs.